Key Financial Figures (Consolidated)
Q2 FY27 Performance (YoY):
- Revenue from operations: ₹47.1 crore (vs. ₹31.3 crore in Q2 FY26), a 50% increase.
- Profit After Tax (PAT): ₹6.6 crore (vs. ₹5.1 crore in Q2 FY26), a 30% increase.
- EBITDA: ₹11.3 crore (vs. ₹6.9 crore in Q2 FY26), a 65% increase.
- EBITDA margin: 24.1% (vs. 21.9% in Q2 FY26), an improvement of 217 basis points.
- PAT margin: 14.0% (vs. 16.2% in Q2 FY26), a decrease of 224 basis points.
Q2 FY27 Performance (QoQ):
- Revenue from operations: ₹47.1 crore (vs. ₹33.7 crore in Q1 FY27), a 40% increase.
- Profit After Tax (PAT): ₹6.6 crore (vs. ₹5.1 crore in Q1 FY27), a 30% increase.
- EBITDA: ₹11.3 crore (vs. ₹8.5 crore in Q1 FY27), a 33% increase.
- EBITDA margin: 24.1% (vs. 25.3% in Q1 FY27), a decrease of 120 basis points.
- PAT margin: 14.0% (vs. 15.0% in Q1 FY27), a decrease of 102 basis points.
Key Financial Figures (Standalone)
Q2 FY27 Performance (YoY):
- Revenue from operations: ₹32.7 crore.
- Profit After Tax (PAT): ₹6.6 crore (vs. ₹4.9 crore in Q2 FY26), a 33.1% increase.
Strategic and Operational Highlights
- The performance is attributed to progress in product registrations, expansion into new markets, additions to the product portfolio, contributions from subsidiaries, and improving utilization of existing manufacturing capacities.
- The company is progressing with the commissioning of its parenterals facility, which is expected to be commissioned after Diwali, subject to operational readiness.
- A proposed preferential issue is mentioned, the proceeds of which will support the company's strategic priorities and provide a foundation for the next phase of expansion.
Forward-Looking Guidance & Commentary
- Management's focus for H2 FY27 will remain on improving capacity utilisation, accelerating execution, expanding product and market presence, strengthening subsidiary performance, and maintaining financial discipline.
- The company reaffirms its long-term ambition to triple its consolidated business over the next three years.